Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice

Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies

“…In another study the authors pursued targeted delivery of NPs carrying a miRNA inhibitor instead of a therapeutic miRNA. In detail, Xue et al (2018) developed a pegylated dendrigraft poly-L-lysine (PEG-DGL) dendrimer functionalized with an early myocardium targeting peptide (AT1) and an antisense oligonucleotide able to inhibit miR-1 (AMO-1) (AT1-PEG-DGL-AMO-1). In vivo results showed that the nanovector was able to target the infarcted mouse heart within 30-60 min after a single i.v.…”

The Role of microRNA in the Development of Ischemic Heart Disease

“…Пока не созданы диагностические панели, основанные на оценке уровней циркулирующих микроРНК, которые были бы более чувствительны, специфичны и экономически выгодны, чем существующие на данный момент маркеры. Использование микроРНК в качестве терапевтической мишени также пока не реализовано, хотя исследования возможности применения антисмысловых олигонуклеотидов, миметиков и ингибиторов микроРНК как лекарственных препаратов ведутся широко во всем мире [96][97][98].…”

Induction of cardiomyocyte proliferation, a new way forward for true myocardial regeneration?

“…Inspired by the observation that post myocardial infarction AT1 levels are increased, Xue et al have developed a nanovector with AT1 targeting peptides on the surface. Armed with miR-1 inhibitors, this nanovector can significantly inhibit miR-1 induced apoptosis in the infarcted region (40). Although only a few cases have been successful to specific delivery miRNAs into the myocardium, we believe with the continuous efforts to develop new delivery vehicles such as polymers, lipid nanoparticles, and extracellular vesicles with difference formulations in combination with difference targeting strategies, it is possible to take full advantage of microRNA therapeutics while minimize their potential side-effect.…”